基于EWGSOP2与EWGSOP1定义的低肌肉量与低肌力对社区老年人影响的研究
本研究对InCHIANTI研究中535名社区老年人进行纵向分析,比较EWGSOP2与EWGSOP1定义下低肌力(LMS)和低肌肉量(LMM)的患病率及其对死亡率和移动残疾的独立贡献。结果显示EWGSOP2定义的LMM/LMS组合患病率低于EWGSOP1(3.2% vs 6.2%),且无论采用哪种标准,肌力正常但肌肉量正常者相比,LMS者死亡风险更高,但肌少症各组分均未显著增加移动残疾风险。
要点
- EWGSOP2定义下LMM/LMS组合患病率为3.2%,低于EWGSOP1的6.2%。
- EWGSOP2标准中LMM(HR 2.69)和LMS(HR 3.18)与死亡率相关,但LMM/LMS组合校正后不显著。
- EWGSOP1标准中仅LMS独立与死亡率相关(HR 4.43)。
核心结论
- EWGSOP2算法降低了以LMM/LMS组合定义的肌少症估计患病率。
- 无论采用何种标准,肌力低而肌肉量正常者相比健壮个体死亡风险更高,证实肌力评估对预后评价具有核心作用。
研究设计与样本
- 对InCHIANTI研究中535名社区老年人的纵向分析。
- 采用Cox回归和log-binomial回归分析死亡率与3年移动残疾(无法行走400米)的关联。
主要发现
- EWGSOP2定义下LMM/LMS组合患病率为3.2%,EWGSOP1为6.2%。
- EWGSOP2标准下,LMM与死亡率相关(HR 2.69,95%CI 1.04-6.94),LMS与死亡率相关(HR 3.18,95%CI 1.44-7.01),LMM/LMS组合校正后不显著(HR 2.95,95%CI 0.86-10.16)。
- EWGSOP1标准下,仅LMS独立与死亡率相关(HR 4.43,95%CI 1.85-10.57)。
- 肌少症各组分均未显著增加移动残疾风险。
关键数值与推荐
- LMS和LMM依据EWGSOP2和EWGSOP1标准定义。
- 移动残疾定义为无法行走400米。
临床怎么用
- 在社区老年预后评估中应重视肌力测量,肌力低而肌肉量正常者亦需关注死亡风险。
- 采用EWGSOP2标准时需注意其肌少症患病率估计低于EWGSOP1。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A universal definition of sarcopenia is still lacking. Since the European criteria have been recently revised, we aimed at studying prevalence of low muscle strength (LMS) and low muscle mass (LMM), as defined according to the European Working Group of Sarcopenia in Older People (EWGSOP) 2 and 1 definitions, and their individual contribution toward mortality and incident mobility disability in a cohort of community-dwelling older people. METHODS: Longitudinal analysis of 535 participants of the InCHIANTI study. LMS and LMM were defined according to the criteria indicated in the EWGSOP2 and 1. Cox and log-binomial regressions were used to examine association with mortality and 3-year mobility disability (inability to walk 400 m). RESULTS: We observed a lower prevalence of the combination LMM/LMS according to EWGSOP2 compared to EWGSOP1 (3.2% vs 6.2%). Using the new criteria, all sarcopenia components were associated with mortality, although the hazard ratio [HR] for the group LMM/LMS was no longer significant after adjustment for confounders (LMM: HR 2.69, 95% confidence interval [CI] 1.04-6.94; LMS: HR 3.18, 95% CI 1.44-7.01; LMM/LMS: HR 2.95, 95% CI 0.86-10.16). Using EWGSOP1, LMS alone was independently associated with mortality (HR 4.43, 95% CI 1.85-10.57). None of the sarcopenia components conferred a higher risk of mobility disability. CONCLUSIONS: The EWGSOP2 algorithm leads to a reduction in the estimated prevalence of sarcopenia defined as combination of LMM/LMS. The finding that, independent of the adopted criteria, people with LMS and normal mass have a higher mortality risk compared to robust individuals, confirms that evaluation of muscle strength has a central role for prognosis evaluation.
引用
- Costanzo L, De Vincentis A, Di Iorio A, et al. Impact of Low Muscle Mass and Low Muscle Strength According to EWGSOP2 and EWGSOP1 in Community-Dwelling Older People. J Gerontol A Biol Sci Med Sci. 2020. PMID: 32157272. doi:10.1093/gerona/glaa063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。